P4ADNow is a bipartisan patient advocacy organization fighting for lower drug prices. We mobilize patients in support of legislation to fix our broken system.
Washington, DC
Joined December 2017
- Tweets3.4K
- Following1.1K
- Followers2.3K
- Likes1.3K
Pinned Tweet
NEW VIDEO: We just released a new video explaining one of the most important — and least talked about — drivers of high drug prices: patent abuse. The ETHIC Act would close the loopholes drug companies exploit to block cheaper generics. Watch, share, and urge Congress to act: tinyurl.com/e3kr3vv2
The third round of Medicare drug price negotiations will end on November 1, five days before the midterms and healthcare costs remain a major voter concern, with polling showing they could influence decisions at the ballot box, and CMS will broaden the agency’s Cell and Gene Therapy Access Model beyond Genetix Biotherapeutics and Vertex’s sickle cell disease therapies. Read more at our Week in Review: tinyurl.com/mak8u7eb
Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: tinyurl.com/mubcwjd
Patients For Affordable Drugs NOW retweeted
🚨Exciting healthcare affordability news!!! 🚨
Patent thickets are a major obstacle to biosimilar drugs entering the market (which lower costs). Biologic medicines in particular are a massive cost driver of prescription drug spending for everyone, despite being used by less patients with less frequency than nonbiologic generics. Because loopholes in the patent process (federal law) are the problem here, allowing lawsuits to be structured en masse and sequentially in a massive delay tactic scam, only Congressional action can fix this problem.
So this bipartisan bill is a long overdue policy solution that will absolutely lower drug prices on some of our most unaffordable drugs, leading to lower pharmaceutical spend by employers and ultimately lower healthcare costs for all.
Kudos to @SenPeterWelch @HawleyMO @amyklobuchar @RepArrington!! Let’s all get behind them and get the Ethic Act passed!!!!
What's one of the biggest drivers of high drug prices? 🤔
Big drug company patent abuse.
The P4AD-endorsed ETHIC Act would close a loophole drug companies exploit to block cheaper generics from coming to market and lowering costs for patients. Watch, share, and urge Congress to act: tinyurl.com/hrdw4ctz
Patients For Affordable Drugs NOW retweeted
We're currently in the lead for a 2026 Anthem Award, but the competition is catching up!
Selected from more than 2,500 projects, we’re proud to see this work recognized alongside other campaigns driving social impact. But we need your help!
Voting is open through October 29. Don’t forget to verify your email after voting to make sure your vote counts!
Thank you for helping us keep up the fight for lower prescription drug prices! #AnthemAwards @anthemawards
celebrate.anthemawards.com/P…
CVS owns pharmacies, operates one of the country's largest PBMs, and controls a major health insurer.
As Rep. Ocasio-Cortez explains, this kind of market concentration raises serious questions about competition, costs, and who benefits.
Patients across the country are struggling to afford their medications. We need more transparency and accountability across the prescription drug supply chain to bring costs down.
There are several bipartisan bills in Congress right now that could help bring down the cost of prescription drugs.
Drug companies deploy manipulative tactics to delay or block lower-cost competition to keep their prices high P4AD has been pushing for legislation to address some of Big Pharma’s patent schemes. Help us rein in the pharmaceutical industry’s monopoly power.
Urge your Senators to support patent reform. Take action today by sending a letter!
actionnetwork.org/letters/te…
Launch price of drugs jumped 35% between 2022-2025, after the Fifth Circuit rejected PhRMA’s challenge this summer, the group filed an en banc petition, and Maryland Gov. backed legislation allowing the state’s PDAB to set upper payment limits based on prices negotiated by Medicare. Read more at our Week in Review: tinyurl.com/3pyshntz
Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: tinyurl.com/mubcwjd
Big Pharma's abuse of the patent system has made it harder for generics and biosimilars to come to market to lower drug prices for patients, but the bipartisan Eliminating Thickets to Improve Competition (ETHIC) Act could help change that.
The ETHIC Act addresses double patenting by allowing a generic manufacturer to challenge only one key patent in a patent family to invalidate duplicative patents. Helping to close a loophole that Big Pharma has relied on to block competition and keep prices artificially high.
Big Pharma’s army of lobbyists is working to stop common-sense reforms like the ETHIC Act. Make sure they don’t get their way -- send a letter to your representative urging them to support ETHIC today: tinyurl.com/3bynbf37
CEO Merith Basey sat down with Ken Rosato from @onnewjersey to discuss the drug pricing crisis in the United States. Merith shares the story behind P4AD, how we got started, our key priorities, and what we’re hoping to achieve.
Still have questions or want to get involved? We’d love to hear from you! Send us a DM. 💬
💔 Patients like Beck shouldn't have to ration their insulin due to cost, and yet, stories like hers are all too common.
Insulin is essential for people with diabetes, but many people with private insurance still face high out-of-pocket costs. The bipartisan INSULIN Act would cap monthly insulin costs at $35 for people with private insurance, helping make this lifesaving medication more affordable.
Patients and families deserve to be heard. Write to your members of Congress and urge them to pass the INSULIN Act: actionnetwork.org/letters/te…
Hispanic and Latino communities are disproportionately harmed by high drug prices, but make up just a fraction of the patient advocates fighting back against big drug companies. Get involved, stand with other patients, and lend your voice to help change policy! Share your story with P4AD: actionnetwork.org/forms/base…
Las comunidades hispanas y latinas se ven afectadas de manera desproporcionada por los altos precios de los medicamentos, pero representan solo una pequeña parte de los pacientes defensores que luchan contra las grandes compañías farmacéuticas. ¡Involúcrate, únete a otros pacientes y alza tu voz para ayudar a cambiar las políticas! Comparte tu historia con P4AD: actionnetwork.org/forms/base…
CBP announced that it is delaying a change in personal implementation requirements by 90 days, nearly 40% of FDA advisory meetings included patient representatives tied to Big Pharma-funded advocacy groups, and a new industry-backed bill would make it easier for certain biologic drugs to delay their eligibility for Medicare negotiation. Read more at our Week in Review: tinyurl.com/yykc3fdf
Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: tinyurl.com/mubcwjd
What's one of the biggest drivers of high drug prices? 🤔
Big drug company patent abuse.
The P4AD-endorsed ETHIC Act would close a loophole drug companies exploit to block cheaper generics from coming to market and lowering costs for patients. Watch, share, and urge Congress to act: tinyurl.com/hrdw4ctz
💔 Sa'Ra and her sister have been forced to share insulin because of the unaffordable price. This is unacceptable, yet stories like theirs are all too common. According to a 2024 report from T1International, nearly 37% of respondents reported rationing insulin due to cost.
The bipartisan INSULIN Act would establish a $35 monthly out-of-pocket cap for insulin for people with private insurance, making this lifesaving medication more affordable and reducing barriers to care.
Send a letter to your members of Congress today and urge them to pass the bipartisan INSULIN Act: actionnetwork.org/letters/te…
The Medication Affordability and Patent Integrity Act (S. 2658) would strengthen oversight of the patent system and close loopholes that delay competition.
When competition enters the market, prices go down significantly.
In fact, when there are six or more generic competitors on the market to compete with brand-name products, prices can fall by up to 95%.
That’s why P4AD supports this bill. Write a letter to your Senator today in support of The Medication Affordability and Patent Integrity Act: actionnetwork.org/letters/te…
Patients For Affordable Drugs NOW retweeted
Big news! Our US v. Pharma: Fighting to Protect Medicare Negotiation campaign has been named a finalist for the Anthem Awards!
Medicare drug price negotiation is a historic step toward lowering prescription drug prices, but the policy can be complex and difficult to connect with audiences beyond Medicare beneficiaries. That’s why we partnered with digital creators to bring this issue to life through authentic storytelling and make it more accessible and relevant to younger and more diverse audiences.
Selected from more than 2,500 projects, we’re proud to see this work recognized alongside other campaigns driving social impact. Now, we need your help!
Vote for P4AD for the Anthem Community Voice Award and help us celebrate this work: celebrate.anthemawards.com/P…
Voting is open through October 29. Don’t forget to verify your email after voting to make sure your vote counts!
Thank you for helping us keep up the fight for lower prescription drug prices! #AnthemAwards @anthemawards
AstraZeneca revived one of its multiple lawsuits against Medicare negotiation, PhRMA filed a lawsuit challenging the Trump administration’s GLOBE model, and new KFF polling confirms that healthcare costs remain Americans’ top affordability concern. Read more at our Week in Review: tinyurl.com/xkbhtjv6
Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: tinyurl.com/mubcwjd
P4AD patient advocate Jackie relies on the 2022 prescription drug law's $2,000 cap on out of pocket costs to afford the medication she needs to survive. To learn more about the 2022 prescription drug law and how it's helping patients save money at the pharmacy, visit MedicareNegotiation.org
Use your voice to help change policy! Every story contributes to the larger picture of what real patients are facing and helps build a stronger, more powerful movement for change. Share your story with P4AD: actionnetwork.org/forms/base…
¡Usa tu voz para cambiar las políticas! Cada historia contribuye a construir una imagen más completa de lo que enfrentan los pacientes en la vida real y ayuda a construir un movimiento más fuerte y poderoso para impulsar cambio. Comparte tu historia con P4AD: actionnetwork.org/forms/base…
Humira is a great example of how big drug companies abuse the patent system to extend monopolies, avoid competition, and keep prices high.
9 in 10 Americans are urging Congress to do more to lower the cost of prescription drugs in the U.S. It’s time for Congress to rein in Big Pharma’s unchecked greed and help the millions of patients that have to skip or ration their meds due to their high cost.
GLOBE’s projected Medicare savings fell from $11.9B to just $440M due to Pharma carveouts, 56 members of Congress are urging CMS to weaken Medicare Negotiation, patients respond to the new CBP rule that will make it harder to import lower-cost prescription drugs from abroad, and Eric Cantor named next President and CEO of PhRMA. Read more at our Week in Review: tinyurl.com/ykf79kye
Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: tinyurl.com/mubcwjd
